BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A validation study

Amber Louw, Vasiliki Panou, Weronika Maria Szejniuk, Christos Meristoudis, Siaw Ming Chai, Chris van Vliet, Y. C. Gary Lee, Ian M. Dick, Tina Firth, Louise Andersen Lynggaard, Azadeh Birbaneh Asghari, Mogens Vyberg, Johnni Hansen, Jenette Creaney*, Oluf Dimitri Røe

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

37 Citations (Scopus)
113 Downloads (Pure)

Abstract

INTRODUCTION: Pleural mesothelioma (PM) is an aggressive malignancy with no identified predictive biomarkers. We assessed whether tumor BAP1 status is a predictive biomarker for survival in patients receiving first-line combination platinum and pemetrexed therapy.

METHODS: PM cases (n = 114) from Aalborg, Denmark, were stained for BAP1 on tissue microarrays. Demographic, clinical, and survival data were extracted from registries and medical records. Surgical cases were excluded. BAP1 status was associated with overall survival (OS) by Cox regression and Kaplan-Meier methods. Results were validated in an independent cohort from Perth, Australia (n = 234).

RESULTS: BAP1 loss was found in 62% and 60.3% of all Danish and Australian samples, respectively. BAP1 loss was an independent predictor of OS in multivariate analyses corrected for histological subtype, performance status, age, sex, and treatment (hazard ratio = 2.49, p < 0.001, and 1.48, p = 0.01, respectively). First-line platinum and pemetrexed-treated patients with BAP1 loss had significantly longer median survival than those with retained BAP1 in both the Danish (20.1 versus 7.3 mo, p < 0.001) and Australian cohorts (19.6 versus 11.1 mo, p < 0.01). Survival in patients with BAP1 retained and treated with platinum and pemetrexed was similar as in those with best supportive care. There was a higher OS in patients with best supportive care with BAP1 loss, but it was significant only in the Australian cohort (16.8 versus 8.3 mo, p < 0.01).

CONCLUSIONS: BAP1 is a predictive biomarker for survival after first-line combination platinum and pemetrexed chemotherapy and a potential prognostic marker in PM. BAP1 in tumor is a promising clinical tool for treatment stratification.

Original languageEnglish
JournalJournal of Thoracic Oncology
Volume17
Issue number7
Pages (from-to)921-930
Number of pages10
ISSN1556-0864
DOIs
Publication statusPublished - Jul 2022

Bibliographical note

Copyright © 2022 International Association for the Study of Lung Cancer. All rights reserved.

Keywords

  • BAP1
  • Chemotherapy
  • Pemetrexed
  • Pleural mesothelioma
  • Predictive biomarkers
  • Immunohistochemistry
  • Lung Neoplasms/pathology
  • Humans
  • Pleural Neoplasms/pathology
  • Australia/epidemiology
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Mesothelioma/pathology
  • Pemetrexed/therapeutic use
  • Platinum/therapeutic use
  • Mesothelioma, Malignant
  • Ubiquitin Thiolesterase
  • Tumor Suppressor Proteins

Fingerprint

Dive into the research topics of 'BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A validation study'. Together they form a unique fingerprint.

Cite this